Navigation Links
Genmab Reaches Milestone in Ofatumumab Collaboration
Date:6/30/2008

://www.genmab.com" target="_new">http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted, Sr. Director, Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
2. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
3. Genmab Announces Updates on Phase III Cancer Studies
4. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
5. Bionomics Achieves US$1 Million Milestone Payment from Genmab
6. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
7. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
8. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
9. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
10. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
11. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Qmed.com , the world,s only 100% qualified ... resource, today announced a new powerful business intelligence tool ... as part of its continuing commitment to provide users with ... "I am very pleased to announce that this new regulatory ...
... Mobility (USM) is excited to announce today that it has ... and merge its complex mobility business with USM. USM/TRS will ... Dana Mazer, ATP and his rehab team strengthens our position ... initiative in North Carolina. We are delighted to welcome their ...
Cached Medicine Technology:Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process 2Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process 3
(Date:7/10/2014)... (PRWEB) July 10, 2014 Thousands ... gather in Copenhagen this July 13-17 to reveal ... the world closer to breakthroughs in dementia science. ... world’s largest conference of its kind. , As ... serves as a catalyst for generating new knowledge ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... CBPartners, a global leader in consulting ... new website. The redesigned site boasts improved navigation ... the firm’s thought pieces, blog posts, and conference presentations. ... showcase our insights, capabilities, and to provide timely updates ... Officer, Cyrus Chowdhury. “An enhanced online presence is ...
(Date:7/10/2014)... Best Drug Rehabilitation , ... family close by during a stay in rehab ... not the process is successful, has launched an ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories ... several Best Drug Rehabilitation graduates who wanted to ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... In ... Dr. Abdul Rao , Chief Executive Officer and Chief Research Officer, the Institute ... cross-enterprise electronic platform for timely integration of patient-specific healthcare information. , ... (Vocus) December 14, 2009 -- In ...
... than white women to receive radiation therapy after a lumpectomy, ... to a new study by researchers at The University of ... its kind and the first to examine such racial disparities ... Cancer . It was first presented at the 2008 American ...
... technology could lead to quicker detection and treatment, study ... "nanosensors" can detect early signs of cancer in everyday ... sensors hunted for and picked up biomarkers for prostate ... of the Yale Institute for Nanoscience and Quantum Engineering ...
... SAN ANTONIO - In a large review of breast ... of Texas M. D. Anderson Cancer Center have identified ... long-associated with a favorable prognosis and multiple tumors undetected ... at the CTRC-AACR San Antonio Breast Cancer Symposium, is ...
... ... Treatment Program , ... (PRWEB) December 12, 2009 -- Eighteen year addiction ends at Narconon California Drug Treatment ... prescription drugs for the last eighteen years! Imagine finding that out just before Christmas. ...
... , MEXICO CITY, Dec. 11 Genomma Lab ... its,2010 earnings guidance. , Genomma Lab expects net ... of 2010, excluding possible acquisitions, and an EBITDA margin,between 25.0% and 26.0%, ... guidance. , The Company,s estimates are based on ...
Cached Medicine News:Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 2Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 3Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 4Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 2Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 3Health News:'Nanosensors' Spot Early Signs of Cancer 2Health News:M. D. Anderson study questions true favorability of rare breast cancer type 2Health News:Nurse Celebrates Son's Drug Addiction Recovery During Holidays 2
...
Digital Ultrasonic Diagnostic Imaging System...
...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Medicine Products: